BeiGene hema­tol­ogy CMO Jane Huang makes a quick jump to a strug­gling biotech now jug­gling pipeline projects

Just days af­ter we learned that BeiGene CMO of hema­tol­ogy Jane Huang was plan­ning her ex­it, we now know what she’s do­ing next. Pre­lude Ther­a­peu­tics, a lit­tle biotech fo­cused on can­cer R&D, has re­cruit­ed Huang as its next pres­i­dent and CMO — and they’re back­ing up the play with a chunk of eq­ui­ty.

Ac­cord­ing to an SEC fil­ing, the Genen­tech vet is get­ting a $525,000 a year in salary, a bonus worth up to half of that and 150,000 shares that vest over 4 years — a clas­sic com­bo for top ex­ecs. She al­so gets an op­tion on 460,000 shares that will vest over time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER